On Demand Webinar

Imaging Orthotopic and Metastatic Preclinical Models for Oncology Drug Discovery

Presenter: Rajendra Kumari, PhD - Executive Director, Integrated Solutions

Orthotopic tumor models have many advantages over subcutaneous counterparts, including recapitulating organ-specific tumor microenvironments, and allowing assessment of disease progression and metastasis.

However, orthotopic and/or metastatic model utility can be impacted by difficulties in assessing tumor burden and therapeutic response in deep lying organs. This is overcome through bioluminescent imaging (BLI) of these models using luciferase-transduced cell lines.

In this webinar, Rajendra Kumari will discuss the value of orthotopic/metastatic models in preclinical research. She’ll highlight the many benefits of optical imaging when applied to orthotopic/metastatic models for evaluating novel anticancer agents.

Watch this Webinar to:

• Explore the advantages of orthotopic models, including an organ-specific tumor microenvironment, development of relevant tumor vasculature, and stromal interactions
• Learn how metastatic models provide valuable disease and mechanistic information across a variety of different cancer stages
• Discover how optical imaging allows real-time monitoring of tumor burden and tracking of disease progression, including for deep lying organs such as brain, prostate, and liver
• Explore the insights bioluminescent imaging provides on disease mechanisms, as well as treatment of tumorigenesis and metastasis
• Learn more on the benefits of BLI for in vivo pharmacology studies
• Gain practical knowledge on how to design a preclinical imaging study
• Explore the challenges in developing relevant imaging models and their limitations

Watch Now!

About The Presenter:

Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience

As Executive Director of Integrated Solutions within the Commercial and Strategic Development team, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post-doctoral fellowships and an Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd. in 2010, serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications